...A. We have 3 clinical candidates in advanced stages of development, and we have data readouts anticipated from these candidates with the imminent one being in Q4 of 2024, and that's the AL002 INVOKE-2 Phase II data from early Alzheimer's disease. B. Our progranulin franchise has 2 monoclonal antibodies, latozinemab and AL101, both in Phase -- one in Phase III and one in Phase II, and I'll tell you more about these later. C. Additionally, we have a pipeline of preclinical candidates, and we have our own proprietary blood-brain barrier technology called Alector Brain Carrier or ABC that we are utilizing both for novel targets well to create second-generation programs. D. Particularly because of a real interest this target, we have imminent data coming in Q4 2024. E. Over 40 TREM2 mutations related to AD have been identified, and it's been shown in GWAS studies that elevated TREM2, which reflects a baseline activation of microglia is associated with slower cognitive decline in Alzheimer's...
